Have a look at this infographic that Extedo® and Asphalion have prepared with the summary updates in terms of publishing and eSubmission at a regional level. On this occasion, we are focusing on Taiwan!
As of January 1st, 2020, the use of the eCTD format is mandatory for NDA submissions and voluntary for all other submission types for pharmaceutical, biologic and radiopharmaceutical drugs for human use. At Asphalion we can guide you with the transition to eCTD to be filed for each submission.
ASPHALION and our partner Extedo® can offer you a wide range in Regulatory Services and Solutions in Taiwan, by giving you support in a variety of activities.
You can dowload the document here:
